Tirzepatide dramatically lowers the estimated risk of ASCVD in individuals who are obese but do not have diabetes.

Published Date: 17 Nov 2023

According to the phase 3 trial's findings, tirzepatide treatment for 72 weeks considerably lowered the ASCVD 10-year predicted risk.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Is It Really Cancer? More Concerns About Accelerated Approval; Metformin and Cancer

2.

Pediatric high-grade gliomas: Research reveals effective targeting with avapritinib

3.

In prostate cancer survivorship, sleep disturbances are underappreciated.

4.

Study shows supervised exercise improves strength, physical performance in patients with advanced breast cancer

5.

a cutting-edge cancer diagnostic tool.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot